ZIOPTAN

Peak

tafluprost

NDAOPHTHALMICSOLUTION/DROPS
Approved
Feb 2012
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
14

Mechanism of Action

Prostaglandin Receptor Agonists

Pharmacologic Class:

Prostaglandin Analog

Clinical Trials (5)

NCT04828057N/ACompleted

Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

Started Sep 2021
50 enrolled
Ocular Surface DiseasePrimary Open Angle Glaucoma
NCT04737928N/ACompleted

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

Started Apr 2018
1 enrolled
Glaucoma, Primary Open Angle
NCT03612817Phase 4Completed

Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing

Started Jan 2017
NCT02102750Phase 1Completed

A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

Started Jun 2014
17 enrolled
GlaucomaOcular Hypertension
NCT01254604Phase 3Completed

Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)

Started Dec 2011
190 enrolled
GlaucomaOcular Hypertension

Loss of Exclusivity

LOE Date
May 28, 2029
39 months away
Patent Expiry
May 28, 2029

Patent Records (2)

Patent #ExpiryTypeUse Code
10864159
May 28, 2029
Product
U-778
9999593
May 28, 2029
Product